# Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

> **NCT02397421** · PHASE4 · COMPLETED · sponsor: **University of Dundee** · enrollment: 56 (actual)

## Conditions studied

- Heart Failure
- Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02397421
- **Lead sponsor:** University of Dundee
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02397421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02397421, "Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02397421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*